Britain's GSK forecast growth in 2022 after racking up 1.4 billion pounds ($1.9 billion) in COVID-related sales in 2021, beating quarterly forecasts in its first earnings report since rejecting Unilever's bid for its consumer arm.
The results underscore a comeback for GSK in the race to help fight the COVID-19 pandemic after it failed to bring a vaccine to the market so far. The spin off of the consumer venture with Pfizer has also put the future in focus as boss Emma Walmsley faces pressure from activist investors.
"We have ended the year strongly, with another quarter of excellent performance
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)